- Home
- A-Z Publications
- Current Medicinal Chemistry
- Previous Issues
- Volume 15, Issue 24, 2008
Current Medicinal Chemistry - Volume 15, Issue 24, 2008
Volume 15, Issue 24, 2008
-
-
Editorial
More LessOne of the most exciting scientific frontiers today is that of neurosciences. There is a growing interest in understanding some of the underlying chemistry which can influence the functioning of the human brain, particularly the chemical changes responsible for neurological and mental diseases such as epilepsy, Alzheimer, schizophrenia and depression. Exciting recent developments in proteomics and genomics promise Read More
-
-
-
The Cell Cycle Molecules Behind Neurodegeneration in Alzheimer's Disease: Perspectives for Drug Development
Authors: A. Copani, S. Guccione, L. Giurato, F. Caraci, M. Calafiore, M. A. Sortino and F. NicolettiAlzheimer's disease (AD), the leading cause of senile dementia, has become a considerable social and economical problem. Current AD therapeutics provide mainly symptomatic short-term benefit, rather than targeting disease mechanisms. The hallmarks for AD are ß-amyloid plaques, neurofibrillary tangles, and regionalized neuronal loss. Additional neuropathological features have been described that may pro Read More
-
-
-
Acetylcholinesterase Inhibitors as Disease-Modifying Therapies for Alzheimer's Disease
More LessThe therapeutic arsenal for the treatment of Alzheimer's disease (AD) remains confined to a group of four inhibitors of AChE and one NMDA receptor antagonist, which are used to provide a relief of the very late symptoms of the dementia, i.e. the cognitive and functional decline. In line with the growing body of evidence of the pivotal role of the β-amyloid peptide (Aβ) in the pathogenesis of AD, alternative classes of drug Read More
-
-
-
Computational Models of Neuronal Biophysics and the Characterization of Potential Neuropharmacological Targets
Authors: Michele Ferrante, Kim T. Blackwell, Michele Migliore and Giorgio A. AscoliThe identification and characterization of potential pharmacological targets in neurology and psychiatry is a fundamental problem at the intersection between medicinal chemistry and the neurosciences. Exciting new techniques in proteomics and genomics have fostered rapid progress, opening numerous questions as to the functional consequences of ligand binding at the systems level. Psycho- and neuro-activ Read More
-
-
-
Strategy for a Genetic Assessment of Antipsychotic and Antidepressant- Related Proarrhythmia
Authors: Antonio Drago, Fabrizio De Ponti, Giuseppe Boriani, Diana De Ronchi and Alessandro SerrettiAntidepressants and antipsychotics may affect several ion channels involved in the control of cardiac action potential and be proarrhythmic. In this field, accurate understanding of genetics, which per se is a non-controllable risk factor, may help clinicians to prevent life-threatening side effects. So far, a number of genes have been associated with arrhythmia: SCN5A, SCN4B, CACNL1AC, KCNH2, KCNQ1, KCNE1, ANK2, ALG10, KC Read More
-
-
-
The Involvement of Prostaglandins and Nitric Oxide in the Development of Brain Excitability: A Relationship Study
By Anna CapassoThe possible role of PGs and NO in the development of S&W of DBA/2J mice was investigated by evaluating the effects of dexamethasone, indometacin, mifepristone plus dexamethasone on the S&W, as well as of L-NAME both on the S&W in the electrocorticogram of DBA/2J mice and on morphine- and deltorphin II-induced EEG seizure in rabbits. The results of our data indicate that: a) Both dexamethasone and indome Read More
-
-
-
Budesonide: Teaching an Old Dog New Tricks for Inflammatory Bowel Disease Treatment
Authors: Erika Angelucci, Alberto Malesci and Silvio DaneseCrohn's disease and ulcerative colitis are chronic relapsing inflammatory bowel diseases with extremely great variability in presentation and clinical course. For many decades, corticosteroids and aminosalicylates have been the mainstay of the treatment for both Crohn's disease and ulcerative colitis, for the induction and maintenance of remission, respectively. The main limiting factors for the repeated use of corticosteroids or Read More
-
Volumes & issues
-
Volume 32 (2025)
-
Volume 31 (2024)
-
Volume 30 (2023)
-
Volume 29 (2022)
-
Volume 28 (2021)
-
Volume 27 (2020)
-
Volume 26 (2019)
-
Volume 25 (2018)
-
Volume 24 (2017)
-
Volume 23 (2016)
-
Volume 22 (2015)
-
Volume 21 (2014)
-
Volume 20 (2013)
-
Volume 19 (2012)
-
Volume 18 (2011)
-
Volume 17 (2010)
-
Volume 16 (2009)
-
Volume 15 (2008)
-
Volume 14 (2007)
-
Volume 13 (2006)
-
Volume 12 (2005)
-
Volume 11 (2004)
-
Volume 10 (2003)
-
Volume 9 (2002)
-
Volume 8 (2001)
-
Volume 7 (2000)
Most Read This Month
Article
content/journals/cmc
Journal
10
5
false
en
